# Novartis Pharmaceuticals Corporation – FDA Inspection, Aug 21, 2019

Source: https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/e4fab4a0-2d49-44f2-a6c8-f6170fd44cd2
Source feed: FDA_Inspections

> FDA inspection 1100101 of Novartis Pharmaceuticals Corporation, August 21, 2019. Classification: Voluntary Action Indicated (VAI). 4 citations under 21 CFR part 211. Form 483 issued. 4 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1100101
- Company Name: Novartis Pharmaceuticals Corporation
- Inspection Date: 2019-08-21
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Human Cellular, Tissue, and Gene Therapies
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 4

## Related Documents

- [FDA Inspection 1300144 - 2026-02-06](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/dda9986d-7403-4915-9abe-66007c22736d)
- [FDA Inspection 1245942 - 2024-08-08](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/d2f19248-2be2-424d-85b3-a50251928268)
- FDA Inspection 1194474 - 2022-12-09
- [FDA Inspection 1019194 - 2017-04-07](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/9ab30769-64e6-41c7-bcc0-e04710bf5034)

## Related Officers

- [Company Rep](https://www.keypedia.com/people/jacqueline-m-diaz-albertini/9ff937fe-4e9b-445a-80fa-e26800d923b8)
- [Company Rep](https://www.keypedia.com/people/kimberly-l-schultz/2d000290-f49c-4cfd-b8f8-3f4d71f76324)
- [Issuing Officer](https://www.keypedia.com/people/susan-m-jackson/2a4e01d1-8761-4d40-b493-69a4163473bb)

Company: https://www.keypedia.com/companies/novartis-pharmaceuticals-corporation/21559fd5-35ed-4cbd-b228-623dd76bcf47

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d